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Authors’ reply
Birgitte Offersen and Jens Overgaard 
argue that 26 Gy in five fractions is 
biologically inferior to 40 Gy in 15 
fractions on the basis of α/β point 
estimates; however, therapeutic ratio 
is better defined clinically. In the FAST-
Forward trial,1 pre-defined non-
inferiority of the 1 week schedule, 
compared with a 15 fraction control 
for ipsilateral breast tumour relapse, 
was substantiated. Combined with 
similar rates of late adverse effects for 
patients allocated to the 26 Gy 
schedule, why not be guided by the 
data?
Point estimates of α/β values for 
late normal tissue effects scored by 
clinicians, patients, and photographic 
assessments in the FAST-Forward1, 
START,2 and FAST3 trials have 95% CIs 
that overlap for each endpoint in all 
five trials; however, let us assume that 
the estimated α/β value of 2 Gy for 
late normal tissue effects of the 5 day 
schedule is accurate. In this case, 26 Gy 
in five fractions is equivalent to 47 Gy 
in 2 Gy fractions, causing 10–15% 
fewer late adverse effects than the 
earlier standard 50 Gy in 25 fractions 
still in use. Based on a tumour α/β 
value of 3·5 Gy estimated directly in 
the START-P and START-A trials, 40 Gy 
in 15 fractions should have also been 
biologically inferior; however, it was 
clinically non-inferior for ipsilateral 
breast tumour relapse (hazard ratio 
0·77, 95% CI 0·51–1·16) and slightly 
milder for late normal tissue effects, 
including clinician-assessed breast 
shrinkage (0·80, 0·67–0·96).2 Post-
hoc analysis suggests a significant 
overall time effect for ipsilateral breast 
tumour relapse only, corresponding to 
a wasted dose of 0·6 Gy/day (95% CI 
0·10–1·18, p=0·02) when the 5 week 
schedule is used.4 If true, something 
similar could be considered in the 
FAST-Forward trial. Repopulation is 
the probable biological mechanism if 
surgical resection, systemic therapies, 
or both, stimulate tumour 
proliferation in the weeks or months 
before radiotherapy. 
Offersen and Overgaard also raise 
the need for radiotherapy in 
subgroups of patients at low risk; such 
consideration is a separate question 
and is addressed in other ongoing 
trials. 
Michael Douek and colleagues 
question the trial design of FAST-
Forward. The purpose of the two-test 
group design is that a regimen of five 
fractions can be found to be 
isoeffective with control, by 
interpolation if necessary. Hazard 
ratios for late normal tissue effects in 
the START trials did not change 
between 5 years and 10 years.2 
Intraoperative radiotherapy is not 
relevant to our trial and the questions 
that it addresses.
We welcome comments from 
Shearwood McClelland III; although 
results from the FAST-Forward trial 
are applicable to all subgroups of 
patients tested, the Correspondence 
highlights access to radiotherapy and 
favourable therapeutic ratio as the 
most important clinical 
considerations. 
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